Skip to main content

Table 1 Univariable and multivariable analysis of risk factors for phenotypic pyrazinamide resistance

From: Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China

CharacteristicAll cases
n (%)
Pyrazinamide- susceptible
n (%)
Pyrazinamide resistant
n (%)
Crude
Prevalence ratio (95% CI)
Adjusted
Prevalence ratio (95%CI)
P value
Gender
 Male211 (65.1)129 (62.7)82 (62.1)1.01.0 
 Female113 (34.9)63 (32.8)50 (37.9)1.14 (0.88–1.49)1.08 (0.82–1.42)0.59
Age (years)
 <40153 (47.2)82 (42.7)71 (53.8)1.01.0 
 40–59108 (33.3)63 (32.8)45 (34.1)0.90 (0.68–1.19)0.86 (0.65–1.14)0.3
6063 (19.4)47 (24.5)16 (12.1)0.55 (0.35–0.86)0.54 (0.34–0.87)0.01
Residential area within China
 East104 (32.1)65 (33.9)39 (29.5)1.0NA 
 Central162 (50.0)94 (49.0)68 (51.5)1.12 (0.82–1.52)NA 
 West58 (17.9)33 (17.2)25 (18.9)1.45 (0.78–1.69)NA 
Occupation
 Farmer202 (62.3)129 (67.2)73 (55.3)1.0NA 
 Other122 (37.7)63 (32.8)59 (44.7)1.34 (1.03–1.73)NA 
Residence in area according to start DOTS implementation
 In 2000 or later187 (57.7)106 (55.2)81 (61.4)1.0NA 
 Before 2000137 (42.3)86 (44.8)51 (38.6)0.86 (0.66–1.13)NA 
Number of previous anti-TB treatments
 0132 (40.7)79 (41.1)53 (40.2)1.01.0 
 1107 (33.0)67 (34.9)40 (30.3)0.93 (0.68–1.28)0.96 (0.70–1.33)0.82
  > 181 (25.0)44 (22.9)37 (28.0)1.14 (0.83–1.56)1.20 (0.88–1.64)0.24
 Unknown4 (1.2)2 (1.0)2 (1.5)1.25 (0.46–3.39)1.30 (0.46–3.66)0.62
Previous pyrazinamide usage
 Yes144 (44.4)87 (45.3)57 (43.2)1.0NA 
 No180 (55.6)105 (54.7)75 (56.8)1.06 (0.81–1.38)NA 
Genotype
 Non-beijing strain42 (13.0)27 (14.1)15 (11.4)1.0NA 
 Beijing strain230 (71.0)133 (69.3)97 (73.5)0.90 (0.70–1.16)NA 
 Unknown52 (16.0)32 (16.7)20 (15.2)0.96 (0.70–1.31)NA 
  1. NA not applicable, these variables were not included in the final model